Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
ADNOC Gas Targets Up to $4B Profit in 2026 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SAN DIEGO, Feb. 21, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2017 financial and operating results after the close of U.S. financial markets on Wednesday, February 28, 2018. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2018 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 1894785 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact:
Casey Logan
Chief Business Officer
(858) 550-0780 ext. 236
[email protected]
Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
[email protected]
